Volitionrx LTD VNRX
Institutional shares held
21.2 Million
0
calls
0
puts
Total value of holdings
$10.4M
$0
calls
$0
puts
Market Cap
$28.1M
57,297,000
Shares Out.
Institutional ownership
37.05%
# of Institutions
24
We take great care to ensure that the data presented and summarized in this overview for VOLITIONRX LTD is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VNRX
View all-
Lagoda Investment Management, L.P. New York, NY10.2MShares$5 Million3.7% of portfolio
-
Armistice Capital, LLC New York, NY8.21MShares$4.02 Million0.07% of portfolio
-
Geode Capital Management, LLC Boston, MA762KShares$373,3550.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA706KShares$345,9690.0% of portfolio
-
Black Rock Inc. New York, NY516KShares$252,8750.0% of portfolio
-
Cowen Prime Advisors LLC179KShares$87,5810.09% of portfolio
-
State Street Corp Boston, MA148KShares$72,3420.0% of portfolio
-
Silverberg Bernstein Capital Management LLC Armonk, NY141KShares$68,8800.07% of portfolio
-
Northern Trust Corp Chicago, IL118KShares$57,7580.0% of portfolio
-
Ubs Group Ag83.2KShares$40,7570.0% of portfolio
Latest Institutional Activity in VNRX
Top Purchases
Top Sells
About VNRX
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
Insider Transactions at VNRX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 19
2025
|
Jacob Vincent Micallef Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
50,000
+10.5%
|
$0
$0.43 P/Share
|
|
May 19
2025
|
Cameron John Reynolds President and CEO |
BUY
Open market or private purchase
|
Direct |
20,000
+0.86%
|
$0
$0.44 P/Share
|
|
May 01
2025
|
Jacob Vincent Micallef Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
18,319
-4.65%
|
$0
$0.49 P/Share
|
|
May 01
2025
|
Gael Forterre Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,698
-2.27%
|
$0
$0.49 P/Share
|
|
May 01
2025
|
Salvatore Thomas Butera CEO, Volition Veterinary |
SELL
Payment of exercise price or tax liability
|
Direct |
10,205
-3.26%
|
$0
$0.49 P/Share
|
|
May 01
2025
|
Rodney Gerard Rootsaert Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
5,453
-3.81%
|
$0
$0.49 P/Share
|
|
May 01
2025
|
Andrew Retter Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,913
-2.84%
|
$0
$0.49 P/Share
|
|
May 01
2025
|
Michel Gaetan Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,844
-1.73%
|
$0
$0.49 P/Share
|
|
Mar 26
2025
|
Guy Archibald Innes |
BUY
Open market or private purchase
|
Direct |
181,818
+17.31%
|
$0
$0.55 P/Share
|
|
Mar 26
2025
|
Cameron John Reynolds President and CEO |
BUY
Open market or private purchase
|
Direct |
181,818
+7.33%
|
$0
$0.55 P/Share
|
|
Mar 01
2025
|
Terig Hughes Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,969
+3.46%
|
-
|
|
Mar 01
2025
|
Guy Archibald Innes |
BUY
Grant, award, or other acquisition
|
Direct |
19,786
+2.8%
|
-
|
|
Mar 01
2025
|
Gael Forterre Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,523
+3.28%
|
-
|
|
Mar 01
2025
|
Salvatore Thomas Butera CEO, Volition Veterinary |
BUY
Grant, award, or other acquisition
|
Direct |
19,300
+5.81%
|
-
|
|
Mar 01
2025
|
Ethel Rubin |
BUY
Grant, award, or other acquisition
|
Direct |
9,893
+22.78%
|
-
|
|
Mar 01
2025
|
Andrew Retter Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,142
+6.86%
|
-
|
|
Mar 01
2025
|
Jasmine Kway CEO - Singapore Volition |
BUY
Grant, award, or other acquisition
|
Direct |
16,708
+8.38%
|
-
|
|
Mar 01
2025
|
Alan Colman |
BUY
Grant, award, or other acquisition
|
Direct |
14,840
+5.7%
|
-
|
|
Mar 01
2025
|
Ann Louise Batchelor Group Chief Marketing Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,233
+9.94%
|
-
|
|
Mar 01
2025
|
Kim Nguyen |
BUY
Grant, award, or other acquisition
|
Direct |
9,893
+10.27%
|
-
|
Last 12 Months Summary
Buy / Acquisition
4.14M
Shares
From
23
Insiders
| Grant, award, or other acquisition | 2.71M shares |
|---|---|
| Bona fide gift | 400K shares |
| Open market or private purchase | 1.03M shares |
Sell / Disposition
510K
Shares
From
9
Insiders
| Bona fide gift | 400K shares |
|---|---|
| Payment of exercise price or tax liability | 110K shares |